NEWSROOM

ALL Press Release Awards Media Center

Media Center

2025. 05. 19

Pharma Boardroom Interview with Innorna CEO Dr. Linxian Li: The Strategic Transformation Journey of Innorna

Press Release

2025. 05. 13

Innorna to Present Advances in mRNA-LNP Therapies for PFIC2 and Wilson’s Disease at ASGCT 2025 Annual Meeting

Press Release

2025. 03. 22

Innorna Awarded "2025 Forbes China Leading Enterprises in Industry Development"

Press Release

2025. 03. 14

Innorna Announces FDA Orphan Drug Designation Granted to IN013 for Treatment of Wilson Disease

Press Release

2025. 02. 21

Innorna Announces FDA Rare Pediatric Disease Designation Granted to IN013 for Treatment of Wilson Disease

Press Release

2024. 11. 20

Innorna Announces FDA Orphan Drug Designation Granted to IN015 for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Press Release

2024. 11. 13

Innorna Announces First Participant Dosed in Phase 1 Clinical Trial of Investigational Bivalent RSV mRNA Vaccine IN006

Press Release

2024. 11. 01

Innorna Announces U.S. FDA Rare Pediatric Disease Designation Granted to IN015 for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Press Release

2024. 07. 30

Innorna Announces Orphan Drug Designation Granted to IN016 for the Treatment of Progressive Familial Intrahepatic Cholestasis

Press Release

2024. 07. 23

Innorna Receives IND Clearance for IN001 Herpes Zoster mRNA Vaccine in China

Press Release

2024. 07. 19

Innorna Announces U.S. FDA Orphan Drug Designation Granted to IN022 for the Treatment of Homocystinuria

Press Release

2024. 07. 11

Innorna Announces U.S. FDA Rare Pediatric Disease Designation Granted to IN016 for the Treatment of Progressive Familial Intrahepatic Cholestasis